摘要
目的探究不同体质量指数(BMI)的2型糖尿病(T2DM)患者应用利拉鲁肽注射液治疗的临床疗效及安全性。方法100例T2DM患者,按照患者BMI不同分为正常BMI组(BMI<24 kg/㎡,31例)、超重组(24~28 kg/㎡,36例)和肥胖组(BMI>28 kg/㎡,33例)。三组患者均在胰岛素常规剂量治疗基础上增加利拉鲁肽注射液治疗。比较两组患者治疗前后的血糖水平、BMI、药物不良反应发生情况。结果治疗后,正常BMI组患者空腹血糖(7.82±0.94)mmol/L、餐后2 h血糖(10.93±1.17)mmol/L、糖化血红蛋白(7.23±0.65)%均高于超重组的(6.78±0.91)mmol/L、(9.22±1.24)mmol/L、(6.46±0.52)%和肥胖组的(6.68±0.89)mmol/L、(9.36±1.29)mmol/L、(6.50±0.58)%,差异均具有统计学意义(P<0.05)。治疗前,正常BMI组、超重组、肥胖组的BMI分别为(22.48±1.52)、(26.28±1.85)、(31.19±1.36)kg/㎡,治疗后分别为(22.67±1.39)、(24.47±1.47)、(27.36±1.32)kg/㎡。治疗前后,三组患者BMI比较差异均具有统计学意义(P<0.05),且治疗后超重组和肥胖组均低于治疗前,差异具有统计学意义(P<0.05)。正常BMI组患者治疗前后BMI比较,差异无统计学意义(P>0.05)。三组药物不良反应发生率比较,差异均无统计学意义(P>0.05)。结论利拉鲁肽在超重、肥胖T2DM患者的治疗中具有更好的血糖控制效果,同时该药物还有一定的减重效果,应用安全性较高,适合超重、肥胖的糖尿病患者使用。
Objective To investigate the efficacy and safety of liraglutide injection in type 2 diabetes mellitus(T2DM)patients with different body mass(BMI)index.Methods A total of 100 patients with T2DM were divided into normal BMI group(BMI<24 kg/㎡,31 cases),overweight group(24-28 kg/㎡,36 cases)and obesity group(BMI>28 kg/㎡,33 cases)according to different BMI.All three groups were treated with liraglutide injection on the basis of conventional dose of insulin.The blood glucose and BMI before and after treatment,and occurrence of adverse drug reactions were compared between the two groups.Results After treatment,the fasting blood glucose(7.82±0.94)mmol/L,2 h postprandial blood glucose(10.93±1.17)mmol/L and glycosylated hemoglobin(7.23±0.65)% of normal BMI group were higher than overweight group[(6.78±0.91)mmol/L,(9.22±1.24)mmol/L,(6.46±0.52)%]and obesity group[(6.68±0.89)mmol/L,(9.36±1.29)mmol/L,(6.50±0.58)%],and the difference was statistically significant(P<0.05).Before treatment,the BMI of normal BMI group,overweight group and obesity group were(22.48±1.52),(26.28±1.85)and(31.19±1.36)kg/㎡,which were(22.67±1.39),(24.47±1.47)and(27.36±1.32)kg/㎡ after treatment.Before and after treatment,there was statistically significant difference in BMI among three groups(P<0.05),and the BMI after treatment of overweight and obesity group were lower than those before treatment.All the difference was statistically significant(P<0.05).Before and after treatment,there was no statistically significant difference in BMI in normal BMI group(P>0.05).There was no statistically significant difference in incidence of adverse reactions in three groups(P>0.05).Conclusion Liraglutide has a better glucose control effect in the treatment of overweight and obese T2DM patients.At the same time,it also has a certain weight loss effect.It is safe in application and suitable for overweight and obese diabetic patients.
作者
代丹娇
张华清
陈智伟
汪丽清
DAI Dan-jiao;ZHANG Hua-qing;CHEN Zhi-wei(Department of Endocrinology,Southern University of Science and Technology Hospital,Shenzhen 518000,China)
出处
《中国实用医药》
2021年第15期28-30,共3页
China Practical Medicine
